OncologySTAT: Dr. Cervantes, what were the most important studies in
ovarian cancer that were presented at this year’s ESMO Congress?
Dr. Andres Cervantes: For me, the most important study was the ICON7
trial, which was presented during the presidential session of the ESMO
Congress.1 It was a very important presentation because the paper is the
result of a randomized phase III trial by a large cooperative group.
The study was done within the Gynaecologic Cancer InterGroup, with an
effort of several other cooperative groups, including the British
MRC/NCRI, the leading group. However, also involved were the German
AGO-OVAR, the Australian and New Zealand ANZGOG, the Spanish group for
research in gynecologic and ovarian cancer, GEICO, the French GINECO,
the Scandinavian group NSGO, and the National Cancer Institute of
Canada, NCIC....cont'd
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.